Related Experiment Video
Updated: May 14, 2026

Live-imaging of Breast Epithelial Cell Migration After the Transient Depletion of TIP60
Published on: December 7, 2017
HSP60-mediated UPRmt overactivation drives triptolide-induced hepatocellular lipoapoptosis
Zhichao Yu1, Lan Hu2, Jing Ding2
1School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Background:
The mitochondrial unfolded protein response (UPRmt) maintains proteostasis, but its dysregulation dictates cell fate. This study aimed to elucidate the signaling mechanism by which triptolide (TP), a bioactive component of Tripterygium wilfordii Hook. f., triggers hepatocellular Lipoapoptosis, focusing on HSP60-mediated UPRmt overactivation.
Methods:
A TP-induced mouse liver injury model was established. Serum biochemistry, histopathology, and liver proteomics were performed. Key proteins (HSP60, UPRmt components, SREBP-1c, FASN, cleaved caspase-3) were validated by Western blot and RT-qPCR both in vivo and in AML-12 hepatocytes, while co-immunoprecipitation (Co-IP) was conducted in AML-12 cells. Functional validation used siRNA knockdown.
Results:
TP induced liver injury, lipid deposition, and apoptosis. Proteomic screening implicated UPRmt activation, with HSP60 subsequently validated as a central upregulated component. TP downregulated MFN2 and upregulated HSP60, ClpP, DRP1, SREBP-1c, FASN, and cleaved caspase-3. Co-IP confirmed a direct HSP60-SREBP-1c interaction. Moreover, HSP60 knockdown attenuated the entire TP-induced cascade, including UPRmt overactivation, mitochondrial dysfunction, lipid dysregulation, and apoptosis.
Conclusion:
This study delineates a novel mitochondria-to-nucleus pathway wherein TP induces HSP60-mediated UPRmt overactivation, which promotes SREBP-1c/FASN-driven lipid accumulation, culminating in lipoapoptosis. The "HSP60-UPRmt-SREBP-1c/FASN-lipoapoptosis" axis links dysregulated organelle stress signaling to metabolic cell death. These findings establish HSP60 as a key signaling node and a potential therapeutic target for intercepting this pathological cascade.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
